Myeloma Minute: Dr. Durie's Quick Take on ASCO 2018
| INNOVATION | Latest Research ASCO 2018: Helpful Guidance, But No BreakthroughsAbstracts for the studies to be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting were just released. While no dramatic new findings were reported among the myeloma oral presentations, posters, and educational sessions, there are a number of important updates and helpful discussions to guide practicing clinicians and inform patients. |
|
| Innovation | Research Grant |
| EDUCATION | Event |
Calling All Researchers: Submit Your Grant Applications! |
Regional Community Workshop in Indianapolis |
The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2019 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for applications is Wednesday, August 1, 2018. |
The IMF will conduct a Regional Community Workshop in Indianapolis, IN, on Saturday June 9, 2018. Registration is FREE, but seating is limited. This is a wonderful opportunity to learn from and meet, one-on-one with myeloma experts Rafat Abonour, MD (Indiana University, Indianapolis, IN), Al-Ola A Abdallah, MD (Assistant Professor, Univ. of Kansas Medical Center, Kansas, KS), and Kimberly Odgers Noonan, RN, ANP, AOCN (Dana-Farber Cancer Institute, Boston, MA). |
| Innovation | Latest Research IMF-AbbVie Study on the Role of Genetic Mutation in Outcomes of Myeloma Patients Featured in Oncology TimesOncology Times reports on an IMF study conducted in partnership with AbbVie examining the role of genetic mutation in outcomes of myeloma patients. The primary objective is to determine the overall survival of patients with the t(11;14) translocation, present in an estimated 16 to 24 percent of FISH-tested myeloma cases. “This study has the potential to provide valuable real-world evidence that can help advance care for patients,” says IMF Chairman Dr. Brian G.M. Durie. |
|
| Advocacy | Veterans and Myeloma Blue Water Navy Veterans See Hope for Agent Orange CoverageOn May 8, 2018, the House Veterans Affairs Committee voted unanimously to send H.R. 299, the Blue Water Navy Vietnam Veterans Act of 2017, to the full House for a vote. The bill is expected to pass the House and move to the Senate, where it appears to have the necessary support to make it to the President’s desk for signature. The bill would provide a presumption of exposure to Agent Orange for Navy veterans who served during the Vietnam era within the territorial waters of Vietnam. |
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
|
CLINICAL TRIALS |
EVENTS |
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
May 19-20, 2018 May 24, 2018 June 2, 2018 June 9, 2018 August 24-25, 2018 September 22, 2018 |
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year